ArticleMultiple sclerosis (Houndmills, Basingstoke, England)2020
Association of brain volume loss and long-term disability outcomes in patients with multiple sclerosis treated with teriflunomide.
Article in Multiple sclerosis (Houndmills, Basingstoke, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00803049 (Long-term Extension of the Multinational, Double-blind, Placebo Controlled Study EFC6049), which is not on this map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Long-term Extension of the Multinational, Double-blind, Placebo Controlled Study EFC6049 (HMR1726D/3001) to Document the Safety of Two Doses of Teriflunomide (7 and 14 mg) in Patients With Multiple Sclerosis With Relapses
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Cognitive Impairment in Multiple Sclerosis: The Role of Clinical and Sociodemographic Factors - A Systematic Review and Meta-Analysis.Annals of clinical and translational neurology · 2026Pooled it
- Brain volume loss in relapsing multiple sclerosis: indirect treatment comparisons of available disease-modifying therapies.BMC neurology · 2024Pooled it
- Can earlier biomarker measurements explain a treatment effect on diabetes incidence? A robust comparison of five surrogate markers.BMJ open diabetes research & care · 2023Trial
- Progression-related outcomes of teriflunomide in multiple sclerosis clinical trials.Frontiers in neurology · 2026Review
- Robust evaluation of longitudinal surrogate markers with censored data.Journal of the Royal Statistical Society. Series B, Statistical methodology · 2025Article
- Surrogate Marker Evaluation: A Tutorial Using R.Statistics in medicine · 2025Article
- A systematic literature review of the association between global brain atrophy and the Expanded Disability Status Scale score in people with multiple sclerosis.Therapeutic advances in neurological disorders · 2025Review
- Assessing disease progression and treatment response in progressive multiple sclerosis.Nature reviews. Neurology · 2024Review
- Assessing heterogeneity in surrogacy using censored data.Statistics in medicine · 2024Article
- Robust approach to combining multiple markers to improve surrogacy.Biometrics · 2023Article
- Effects of teriflunomide treatment on cognitive performance and brain volume in patients with relapsing multiple sclerosis: Post hoc analysis of the TEMSO core and extension studies.Multiple sclerosis (Houndmills, Basingstoke, England) · 2022Article
- A Narrative Review on Axonal Neuroprotection in Multiple Sclerosis.Neurology and therapy · 2022Review
- Brain Volume Loss Can Occur at the Rate of Normal Aging in Patients with Multiple Sclerosis Who Are Free from Disease Activity.Journal of clinical medicine · 2022Article
- Smouldering multiple sclerosis: the 'real MS'.Therapeutic advances in neurological disorders · 2022Review
- Longitudinal changes of deep gray matter shape in multiple sclerosis.NeuroImage. Clinical · 2022Article
- The Canadian prospective cohort study to understand progression in multiple sclerosis (CanProCo): rationale, aims, and study design.BMC neurology · 2021Observational
- A Milestone in Multiple Sclerosis Therapy: Monoclonal Antibodies Against CD20-Yet Progress Continues.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2021Review
- Retinal layer thinning predicts treatment failure in relapsing multiple sclerosis.European journal of neurology · 2021Observational
- Article
- Detecting neurodegenerative pathology in multiple sclerosis before irreversible brain tissue loss sets in.Translational neurodegeneration · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTeriflunomide 14 mg significantly reduced brain volume loss (BVL) and confirmed disability worsening (CDW) compared with placebo in the TEMSO core study.
objectiveTo investigate the relationship between BVL from Baseline to Year 2 in the TEMSO core study and long-term CDW (Year 7) in the TEMSO long-term extension (NCT00803049).
methodsStructural Image Evaluation using Normalization of Atrophy determined BVL. Long-term CDW was assessed by Expanded Disability Status Scale confirmed for 12 and 24 weeks. An additional analysis evaluated the relative contribution of BVL (Year 2) and other outcomes as potential mediators of the effect of teriflunomide 14 mg on 12-week CDW.
resultsPatients with the least BVL were significantly less likely to have 12- and 24-week CDW at Year 7 compared with patients with the most BVL. A mediation analysis revealed that BVL (Year 2) explained 51.3% of the treatment effect on CDW; new or enlarging T
conclusionsThese results highlight the potential predictive value of BVL earlier in the disease course on long-term disability outcomes. The mediation analysis suggests that teriflunomide may prevent disability worsening largely through its effects on BVL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.